Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. BA
4. STX
5. NXPI
6. LSTR
7. UPS
8. KIDS
9. V
10. CSGP

Go back to Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results

Protagonist Therapeutics (PTGX) PT Trimmed to $42 at BMO Capital, But Sees Catalyst-Rich 2018

March 8, 2018 5:47 AM EST

BMO Capital analyst M. Ian Somaiya lowered his price target on Protagonist Therapeutics (NASDAQ: PTGX) to $42.00 (from $44.00) while maintaining an Outperform rating.

Somaiya notes Protagonists low risk pipeline is quickly maturing with an interim analysis (futility) of the Phase 2b... More